Emily K Wright1, Michael A Kamm2, Peter De Cruz1, Amy L Hamilton1, Kathryn J Ritchie1, Efrosinia O Krejany1, Alexandra Gorelik3, Danny Liew3, Lani Prideaux1, Ian C Lawrance4, Jane M Andrews5, Peter A Bampton6, Miles P Sparrow7, Timothy H Florin8, Peter R Gibson7, Henry Debinski9, Richard B Gearry10, Finlay A Macrae11, Rupert W Leong12, Ian Kronborg13, Graeme Radford-Smith14, Warwick Selby15, Michael J Johnston1, Rodney Woods1, P Ross Elliott1, Sally J Bell1, Steven J Brown1, William R Connell1, Paul V Desmond1. 1. Department of Gastroenterology, St Vincent's Hospital and University of Melbourne, Melbourne, VIC, Australia. 2. Department of Gastroenterology, St Vincent's Hospital and University of Melbourne, Melbourne, VIC, Australia mkamm@unimelb.edu.au. 3. Melbourne EpiCentre, University of Melbourne and Melbourne Health, Melbourne, VIC, Australia. 4. Centre for Inflammatory Bowel Diseases, Fremantle Hospital and University of Western Australia, Fremantle, WA, Australia. 5. Department of Gastroenterology and Hepatology, Royal Adelaide Hospital and University of Adelaide, Adelaide, SA, Australia. 6. Department of Gastroenterology and Hepatology, Flinders Medical Centre and Flinders University, Adelaide, SA, Australia. 7. Department of Gastroenterology, Alfred Health and Monash University, Melbourne, VIC, Australia. 8. Department of Gastroenterology, Mater Health Services, University of Queensland, Brisbane, QLD, Australia. 9. Melbourne Gastrointestinal Investigation Unit, Cabrini Hospital, Melbourne, VIC, Australia. 10. Department of Medicine, University of Otago, Christchurch, New Zealand. 11. Department of Colorectal Medicine and Genetics, and Department of Medicine, Royal Melbourne Hospital and University of Melbourne, Melbourne, VIC, Australia. 12. Gastroenterology and Liver Services, Concord and Bankstown Hospitals and University of New South Wales, Sydney, NSW, Australia. 13. Department of Gastroenterology, Western Hospital, Melbourne, VIC, Australia. 14. Department of Gastroenterology, Royal Brisbane and Womens Hospital, and IBD Group Queensland Institute of Medical Research, University of Queensland, Brisbane, QLD, Australia. 15. AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Abstract
INTRODUCTION:Patients with Crohn's disease have poorer health-related quality of life [HRQoL] than healthy individuals, even when in remission. Although HRQoL improves in patients who achieve drug-induced or surgically induced remission, the effects of surgery overall have not been well characterised. METHODS: In a randomised trial, patients undergoing intestinal resection of all macroscopically diseased bowel were treated withpostoperative drug therapy to prevent disease recurrence. All patients were followed prospectively for 18 months. C-reactive protein [CRP], Crohn's Disease Activity Index [CDAI], and faecal calprotectin [FC] were measured preoperatively and at 6, 12, and 18 months. HRQoL was assessed with a general [SF36] and disease-specific [IBDQ] questionnaires at the same time points. RESULTS:A total of 174 patients were included. HRQoL was poor preoperatively but improved significantly [p < 0.001] at 6 months postoperatively. This improvement was sustained at 18 months. Females and smokers had a poorer HRQoL when compared with males and non-smokers, respectively. Persistent endoscopic remission, intensification of drug treatment at 6 months, and anti-tumour necrosis factor therapy were not associated with HRQoL outcomes different from those when these factors were not present. There was a significant inverse correlation between CDAI, [but not endoscopic recurrence, CRP, or FC] on HRQoL. CONCLUSION:Intestinal resection of all macroscopic Crohn's disease in patients treated with postoperative prophylactic drug therapy is associated with significant and sustained improvement in HRQoL irrespective of type of drug treatment or endoscopic recurrence. HRQoL is lower in female patients and smokers. A higher CDAI, but not direct measures of active disease or type of drug therapy, is associated with a lower HRQoL.
RCT Entities:
INTRODUCTION:Patients with Crohn's disease have poorer health-related quality of life [HRQoL] than healthy individuals, even when in remission. Although HRQoL improves in patients who achieve drug-induced or surgically induced remission, the effects of surgery overall have not been well characterised. METHODS: In a randomised trial, patients undergoing intestinal resection of all macroscopically diseased bowel were treated with postoperative drug therapy to prevent disease recurrence. All patients were followed prospectively for 18 months. C-reactive protein [CRP], Crohn's Disease Activity Index [CDAI], and faecal calprotectin [FC] were measured preoperatively and at 6, 12, and 18 months. HRQoL was assessed with a general [SF36] and disease-specific [IBDQ] questionnaires at the same time points. RESULTS: A total of 174 patients were included. HRQoL was poor preoperatively but improved significantly [p < 0.001] at 6 months postoperatively. This improvement was sustained at 18 months. Females and smokers had a poorer HRQoL when compared with males and non-smokers, respectively. Persistent endoscopic remission, intensification of drug treatment at 6 months, and anti-tumour necrosis factor therapy were not associated with HRQoL outcomes different from those when these factors were not present. There was a significant inverse correlation between CDAI, [but not endoscopic recurrence, CRP, or FC] on HRQoL. CONCLUSION: Intestinal resection of all macroscopic Crohn's disease in patients treated with postoperative prophylactic drug therapy is associated with significant and sustained improvement in HRQoL irrespective of type of drug treatment or endoscopic recurrence. HRQoL is lower in female patients and smokers. A higher CDAI, but not direct measures of active disease or type of drug therapy, is associated with a lower HRQoL.
Authors: Éanna J Ryan; Gabriel Orsi; Michael R Boland; Adeel Zafar Syed; Ben Creavin; Michael E Kelly; Kieran Sheahan; Paul C Neary; Dara O Kavanagh; Deirdre McNamara; Des C Winter; James M O'Riordan Journal: Int J Colorectal Dis Date: 2020-01-09 Impact factor: 2.571
Authors: Waqas T Butt; Éanna J Ryan; Michael R Boland; Eilis M McCarthy; Joseph Omorogbe; Karl Hazel; Gary A Bass; Paul C Neary; Dara O Kavanagh; Deirdre McNamara; James M O'Riordan Journal: Int J Colorectal Dis Date: 2020-02-11 Impact factor: 2.571
Authors: Emily K Wright; Michael A Kamm; Peter Dr Cruz; Amy L Hamilton; Kathryn J Ritchie; Sally J Bell; Steven J Brown; William R Connell; Paul V Desmond; Danny Liew Journal: World J Gastroenterol Date: 2016-04-14 Impact factor: 5.742
Authors: Cristina Calviño-Suárez; Rocío Ferreiro-Iglesias; Iria Bastón-Rey; Manuel Barreiro-de Acosta Journal: Int J Environ Res Public Health Date: 2021-07-04 Impact factor: 3.390
Authors: Anders Forss; Pär Myrelid; Ola Olén; Åsa H Everhov; Caroline Nordenvall; Jonas Halfvarson; Jonas F Ludvigsson Journal: BMC Med Inform Decis Mak Date: 2019-11-11 Impact factor: 2.796